A prospective study of FOLFIRI plus aflibercept as second-line treatment after failure of FOLFOXIRI plus bevacizumab in patients with unresectable/metastatic colorectal cancer (CRC): EFFORT study

被引：0
|
作者：
Satake, Hironaga
Ando, Koji
Yasui, Hisateru
Negoro, Yuji
Kinjo, Tatsuya
Yuge, Koutarou
Baba, Kenji
Orita, Hiroyuki
Hirata, Keiji
Shimokawa, Mototsugu
Makiyama, Akitaka
Saeki, Hiroshi
Oki, Eiji
Baba, Hideo
机构：
[1] Kochi Med Sch, Dept Med Oncol, Nankoku, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan
[3] Kobe City Med Ctr Gen Hosp, Kobe, Hyogo, Japan
[4] Kochi Hlth Sci Ctr, Div Gastroenterol Med, Kochi, Japan
[5] Univ Ryukyus, Dept Digest & Gen Surg, Fac Med, Nishihara, Japan
[6] Social Insurance Tagawa Hosp, Dept Surg, Tagawa, Japan
[7] Imamura Gen Hosp, Dept Surg, Kagoshima, Japan
[8] Nakatsu Municipal Hosp, Nakatsu, Japan
[9] Univ Occupat & Environm Hlth, Dept Surg 1, Fukuoka, Japan
[10] Yamaguchi Univ, Dept Biostat, Grad Sch Med, Yamaguchi, Japan
[11] Gifu Univ, Gifu, Fukoka, Japan
[12] Gunma Univ Hosp, Maebashi, Japan
[13] Kyushu Univ, Higashi Ku, Fukuoka, Japan
[14] Kumamoto Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, Kumamoto, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3549
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer
    Satake, Hironaga
    Ando, Koji
    Oki, Eiji
    Shimokawa, Mototsugu
    Makiyama, Akitaka
    Saeki, Hiroshi
    Tsuji, Akihito
    Mori, Masaki
    [J]. BMC CANCER, 2020, 20 (01)
  • [2] Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer
    Hironaga Satake
    Koji Ando
    Eiji Oki
    Mototsugu Shimokawa
    Akitaka Makiyama
    Hiroshi Saeki
    Akihito Tsuji
    Masaki Mori
    [J]. BMC Cancer, 20
  • [3] A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer
    Jo, H.
    Lee, M-S
    Lee, Y-P
    Kim, H.
    Hong, J. Y.
    Lee, J.
    Park, S. H.
    Park, J. O.
    Park, Y. S.
    Lim, H. Y.
    Kang, W. K.
    Kim, S. T.
    [J]. CLINICAL ONCOLOGY, 2022, 34 (08) : E323 - E328
  • [4] Predictors of the Efficacy of FOLFIRI plus Bevacizumab as Second-Line Treatment in Metastatic Colorectal Cancer Patients
    Suenaga, Mitsukuni
    Matsusaka, Satoshi
    Ueno, Masashi
    Yamamoto, Noriko
    Shinozaki, Eiji
    Mizunuma, Nobuyuki
    Yamaguchi, Toshiharu
    Hatake, Kiyohiko
    [J]. SURGERY TODAY, 2011, 41 (08) : 1067 - 1074
  • [5] Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients
    Mitsukuni Suenaga
    Satoshi Matsusaka
    Masashi Ueno
    Noriko Yamamoto
    Eiji Shinozaki
    Nobuyuki Mizunuma
    Toshiharu Yamaguchi
    Kiyohiko Hatake
    [J]. Surgery Today, 2011, 41 : 1067 - 1074
  • [6] Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol
    Ottaiano, Alessandro
    Scala, Stefania
    Santorsola, Mariachiara
    Trotta, Anna Maria
    D'Alterio, Crescenzo
    Portella, Luigi
    Clemente, Ottavia
    Nappi, Anna
    Zanaletti, Nicoletta
    De Stefano, Alfonso
    Avallone, Antonio
    Granata, Vincenza
    Notariello, Carmen
    Luce, Amalia
    Lombardi, Angela
    Picone, Carmine
    Petrillo, Antonella
    Perri, Francesco
    Tatangelo, Fabiana
    Di Mauro, Annabella
    Albino, Vittorio
    Izzo, Francesco
    Rega, Daniela
    Pace, Ugo
    Di Marzo, Massimiliano
    Chiodini, Paolo
    De Feo, Gianfranco
    Del Prete, Paola
    Botti, Gerardo
    Delrio, Paolo
    Caraglia, Michele
    Nasti, Guglielmo
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [7] Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer
    Suzuki, Takeshi
    Shinozaki, Eiji
    Osumi, Hiroki
    Nakayama, Izuma
    Ota, Yumiko
    Ichimura, Takashi
    Ogura, Mariko
    Wakatsuki, Takeru
    Ooki, Akira
    Takahari, Daisuke
    Suenaga, Mitsukuni
    Chin, Keisho
    Yamaguchi, Kensei
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (02) : 307 - 313
  • [8] Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer
    Takeshi Suzuki
    Eiji Shinozaki
    Hiroki Osumi
    Izuma Nakayama
    Yumiko Ota
    Takashi Ichimura
    Mariko Ogura
    Takeru Wakatsuki
    Akira Ooki
    Daisuke Takahari
    Mitsukuni Suenaga
    Keisho Chin
    Kensei Yamaguchi
    [J]. Cancer Chemotherapy and Pharmacology, 2019, 84 : 307 - 313
  • [9] FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
    Antoniotti, Carlotta
    Vetere, Guglielmo
    Cremolini, Chiara
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (18)
  • [10] Impact of omitting fluorouracil from FOLFIRI plus bevacizumab in second-line treatment of metastatic colorectal cancer
    Matsubara, Yuki
    Masuishi, Toshiki
    Ogata, Takatsugu
    Nakazawa, Taiko
    Kato, Kyoko
    Nozawa, Kazuki
    Narita, Yukiya
    Honda, Kazunori
    Bando, Hideaki
    Kadowaki, Shigenori
    Ando, Masashi
    Tajika, Masahiro
    Muro, Kei
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S321 - S321
12345